Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADAM10 | O14672 | 16/20 | 0.62 |
| ▸ | MMP2 | P08253 | 13/20 | 0.62 |
| ▸ | MMP8 | P22894 | 1/20 | 0.62 |
| ▸ | MMP12 | P39900 | 1/20 | 0.62 |
| ▸ | ADAM17 | P78536 | 1/20 | 0.62 |
| ▸ | ERBB2 | P04626 | 13/20 | 0.53 |
| ▸ | BACE1 | P56817 | 2/20 | 0.49 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.46 |
| ▸ | MMP9 | P14780 | 2/20 | 0.44 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6500563 | 0.88 | ADAM10 (0.59) | ADAM10MMP2MMP8MMP12ADAM17 | |
| SCHEMBL2173514 | 0.85 | ADAM10 (0.67) | ADAM10MMP2MMP8MMP12ADAM17 | |
| SCHEMBL27651622 | 0.84 | ADAM10 (0.60) | ADAM10MMP2MMP8MMP12ADAM17 | |
| SCHEMBL3456976 | 0.84 | ADAM10 (0.60) | ADAM10MMP2MMP8MMP12ADAM17 | |
| SCHEMBL6344361 | 0.83 | ADAM10 (0.67) | ADAM10MMP2MMP8MMP12ADAM17 | |
| SCHEMBL6336101 | 0.83 | ADAM10 (0.67) | ADAM10MMP2MMP8MMP12ADAM17 | |
| SCHEMBL6336103 | 0.83 | ADAM10 (0.67) | ADAM10MMP2MMP8MMP12ADAM17 | |
| SCHEMBL5664696 | 0.81 | ADAM10 (0.55) | ADAM10MMP2MMP8MMP12ADAM17 | |
| SCHEMBL2172733 | 0.80 | ADAM10 (0.79) | ADAM10MMP2MMP8MMP12ADAM17 | |
| SCHEMBL2172740 | 0.80 | ADAM10 (0.79) | ADAM10MMP2MMP8MMP12ADAM17 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050113344-A1 | Substituted cyclic hydroxamates as inhibitors of matrix metalloproteinases | INCYTE CORPORATION | 2005-05-26 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050113344-A1 | Substituted cyclic hydroxamates as inhibitors of matrix metalloproteinases | MMP25, MMP2, MMP14 | ADAM10 26/4885MMP2 2/4885MMP8 27/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.